BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-101@catalystbrief.girapphe.com
DTSTAMP:20261117T121553Z
LAST-MODIFIED:20261117T121553Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. — SKB
 264 [May 2027]
DESCRIPTION:Phase 3 primary completion: A Study of SKB264 in Combination Wi
 th Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor
  Receptor (EGFR) Mutations\, Locally Advanced or Metastatic Non-Squamous N
 on-Small Cell Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT06
 670196\nhttps://catalystbrief.girapphe.com/e/101?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/101?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
